Dallas, Texas. July 1, 2022:
Following the publication of the article “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress” in Nature Cancer, from the lab of etiraRx co-founder Ganesh Raj, scientific news media was quick to pick up on this major breakthrough in cancer research. In the paper, ERX-41 demonstrates “a large therapeutic window, with no adverse effects either on normal mammary epithelial cells or in mice,” potentially providing a route to treating previously untreatable solid cancers, such as triple-negative breast cancer.
A selection of the news articles which have picked up on the story are below.
